Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia by Schlenk Richard F, Döhner Konstanze, Krauter Jürgen, Fröhling Stefan, Corbacioglu Andrea, Bullinger Lars, Habdank Marianne, Späth Daniela, Morgan Michael, Benner Axel, Schlegelberger Brigitte, Heil Gerhard, Ganser Arnold, Döhner Hartmut, German-Austrian Acute Myeloid Leukemia Study Group in The New England journal of medicine (2008).

[PMID: 18450602] PubMed


Mutations occur in several genes in cytogenetically normal acute myeloid leukemia (AML) cells: the nucleophosmin gene (NPM1), the fms-related tyrosine kinase 3 gene (FLT3), the CCAAT/enhancer binding protein alpha gene (CEPBA), the myeloid-lymphoid or mixed-lineage leukemia gene (MLL), and the neuroblastoma RAS viral oncogene homolog (NRAS). We evaluated the associations of these mutations with clinical outcomes in patients.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.